{"id":"NCT02504541","sponsor":"Antares Pharma Inc.","briefTitle":"Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism","officialTitle":"A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07","primaryCompletion":"2016-06","completion":"2016-06","firstPosted":"2015-07-22","resultsPosted":"2018-03-30","lastUpdate":"2018-03-30"},"enrollment":133,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Testosterone enanthate auto-injector","otherNames":["Testosterone","Testosterone enanthate","QuickShot® Testosterone (QST)"]}],"arms":[{"label":"Testosterone enanthate auto-injector","type":"EXPERIMENTAL"}],"summary":"Evaluation of safety of a concentration controlled testosterone enanthate QuickShot Testosterone regimen administered subcutaneously once each week to adult males with hypogonadism.","primaryOutcome":{"measure":"Incidence of Adverse Events as a Measure of Safety of QuickShot™ Testosterone (QST) Administered Subcutaneously (SC) Once Each Week to Adult Males With Hypogonadism","timeFrame":"26 weeks","effectByArm":[{"arm":"Testosterone Enanthate Auto-injector","deltaMin":87,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":24},"locations":{"siteCount":20,"countries":["United States"]},"refs":{"pmids":["31551193"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":133},"commonTop":["Hematocrit increased","Upper respiratory tract infection","Injection site hemorrhage","Nasopharyngitis","Blood creatine phosphokinase increased"]}}